Skip to main content
Delfa

← All trials/NCT03246451

CompletedPhase NA

The Role of GLP-1 Receptor Signalling in the Glucose-lowering Effect of Metformin in Patients With T2D

The Role of GLP-1 Receptor Signalling in the Glucose-lowering Effect of Metformin During Meal Ingestion in Patients With T2D

Asset

Exenatide

GLP-1 agonist

Listed sites

1

Recruiting sites

-

Actual enrollment

15

Study population

Type 2 diabetes

Eligibility highlights

•BMI 23-35

Primary endpoint

•Postprandial glucose

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT03246451
Org study IDUHG-CFD-METEX

Timeline

Milestones

Study start2017-07-01actual
Study first posted2017-08-11actual
Primary completion2017-12-10actual
Study completion2017-12-10actual
Last update posted2018-07-09actual

Assets

Investigational agents

Exenatide

Who this study enrolls

Type 2 diabetes

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Type 2 diabetes for at least three months (diagnosed according to the criteria of the World Health Organization (WHO)), with a HbA1c <58 mmol/mol.
•Caucasian ethnicity
•Lifestyle intervention and/or metformin monotherapy
•Normal haemoglobin
•Age >18 years
•BMI >23 kg/m2 and <35 kg/m2
•Informed and written consent

Exclusion criteria

•Liver disease
•Gastrointestinal disease, previous intestinal resection, cholecystectomy or any major intra-abdominal surgery
•Hypo- or hyperphosphataemia
•Reduced kidney function or nephropathy
•Treatment with medicine that cannot be paused for 12 hours
•Intake of antibiotics two months prior to study
•Hypo- or hypercalcaemia
•Hypo- and hyperthyroidism
•Treatment with oral anticoagulants
•Active or recent malignant disease
•Any treatment or condition requiring acute or sub-acute medical or surgical intervention
•Lack of effective birth control in premenopausal women
•Positive pregnancy test on study days in premenopausal women
•Pregnancy
•Women who are breastfeeding
•Any condition considered incompatible with participation by the investigators
•If the subjects receive any antibiotic treatment while included in the study they will be excluded

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Glycemic / diabetes

1 endpoint
Primary/protocol endpoint

Plasma glucose

Time frame:Minutes 240

Postprandial glucose

descriptive, improvement

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 6, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.